Compare TKNO & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TKNO | TCPC |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.1M | 273.5M |
| IPO Year | 2021 | 2006 |
| Metric | TKNO | TCPC |
|---|---|---|
| Price | $5.59 | $3.50 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 115.6K | ★ 592.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 18.23% |
| EPS Growth | ★ 43.86 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $13.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $3.08 |
| 52 Week High | $6.68 | $7.28 |
| Indicator | TKNO | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 59.19 | 60.21 |
| Support Level | $4.87 | $3.43 |
| Resistance Level | $5.88 | $3.54 |
| Average True Range (ATR) | 0.37 | 0.11 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 74.77 | 86.96 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.